BTB-202
Long QT syndrome / Cancer immunotherapy enhancement
PreclinicalActive
Key Facts
Indication
Long QT syndrome / Cancer immunotherapy enhancement
Phase
Preclinical
Status
Active
Company
About BTB Therapeutics
BTB Therapeutics is a private, pre-clinical stage biotech leveraging a novel transcriptomics platform to discover small molecule drugs. Its lead program, BTB-101, is a non-opioid analgesic aimed at addressing the opioid crisis, while secondary programs target rare genetic diseases like Cardiac Fabry disease and Long QT syndrome via RNA splicing modulation. The company, founded on academic research from Kyoto University, recently re-domiciled to the US, positioning itself to access larger capital and pharmaceutical markets.
View full company profile